Pharmacogenetic aspects of vildagliptin treatment in patients with newly diagnosed type 2 diabetes mellitus

Pharmacogenetic aspects of vildagliptin treatment in patients with newly diagnosed type 2 diabetes mellitus

Objective: to study a role of the rs5219 polymorphism in KCNJ11 in the formation of the response variability to vildagliptin therapy in patients with newly diagnosed type 2 diabetes mellitus (T2DM).Materials and methods: 48 patients with newly diagnosed T2DM were examined. For all patients vildaglip...

Full description

Bibliographic Details
Main Authors: P. B. Shorokhova, V. L. Baranov, N. V. Vorokhobina, I. Yu. Matezius, E. B. Bashnina, K. A. Jakovenko
Format: Article
Language:English
Published: State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2019-10-01
Series:Медицинский вестник Юга России
Subjects:
type 2 diabetes mellitus
glycated hemoglobin
polymorphism rs5219
kcnj11 gene
dpp-4 inhibitors
Online Access:https://www.medicalherald.ru/jour/article/view/925

Internet

https://www.medicalherald.ru/jour/article/view/925

Similar Items